Status:
NOT_YET_RECRUITING
Attentional Capture by Real-life Episodic Information
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Healthy Volunteers
Attentional Capture
Eligibility:
All Genders
18-40 years
Phase:
NA
Brief Summary
Attention facilitates the allocation of processing resources and the control of behavior among competing stimuli. Current research focuses primarily on attention control networks in the dorsal frontop...
Eligibility Criteria
Inclusion
- Be 18 years old to 40 years old
- Be right-handed
- Do not wear glasses
- Have a mobile-phone compatible with the application, minimum 6rd generation Android operating system, with geo-localization activated and accepted by the user
- Undertake to comply with the instructions and recommendations for MRI examination
- Provide informed written consent to participate in the study
Exclusion
- History of known neurological or psychiatric illness
- Cognitive problems limiting the understanding of instructions
- Recent taking psychotropic drugs (antidepressants, anxiolytics, antipsychotics). The main treatments not authorized during this research are the following: Psychotropic treatments (drugs that can induce changes in perception, sensation, mood, consciousness or behavior). Like what:
- Antipsychotics (valproic acid, amisulpride, aripiprazole, clozapine, cyamemazin, haloperidol, loxapine, olanzapine, risperidone).
- Antidepressants (Amitriptyline, Citalopram, Clomipramine, Duloxetine, Escitalopam, Fluoxetine, Mianserine, Mirtazapine, Nortriptyline, Paroxetine, Sertraline, Venlafaxine).
- Anxyolitics
- Pregnant or breastfeeding women
- Persons deprived of their liberty by a judicial or administrative decision
- Persons admitted to a health or social institution for purposes other than research
- Adults subject to a legal protection measure (guardianship, curatorship)
- Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
- Participation in another research study of the current study
- Contraindication for fMRI scanning
- Participant not agreeing to be informed in the event of the incidental discovery of an anomaly on MRI
- • For visit number 2 :
- Alcohol consumption (\> 3 drinks) in the 24h before the experiment
- Alcohol consumption the day of the experiment
- Cafeine consumption 1 hour or less before the experiment
- Drug consumption within the 24h preceding the experiment
- Antimalarial treatment within the 3 days preceding the experiment
Key Trial Info
Start Date :
December 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 15 2029
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT06934902
Start Date
December 15 2025
End Date
January 15 2029
Last Update
April 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCBL1, CRNL Inserm U1028, CNRS UMR5292, équipe IMPACT
Bron, Rhone, France, 69500